Positive results of PARP inhibitor and CAR T-cell treatments highlight advances in research for neuroblastoma.

Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising ...

The U.S. Food and Drug Administration (FDA) on Monday cleared Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug Application (IND) for a Phase 1b/2 trial for LP-184 in triple-negative breast ...

Mesothelioma is an aggressive cancer that forms in the lining of the lungs or abdomen and is linked to breathing in or ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...

Metastatic castration-resistant prostate cancer (mCRPC) is diagnosed by blood tests, imaging scans, and biopsies. Find out ...

Pancreatic cancer remains one of the most formidable oncological challenges of our time. Known for its late detection and ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...